Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Daltonics, AXS Posts Q2 Revenue, R&D Growth

NEW YORK, Aug. 7 (GenomeWeb News) - Bruker Biosciences' Daltonics division saw its second-quarter revenue grow more than 23 percent year over year, and its Bruker AXS unit grew more than 10 percent. Bruker Daltonics and Bruker AXS merged last month to form Bruker Biosciences.


Total revenue at the Daltonics division for the period ended June 30 grew to $34.4 million from $28 million in the same quarter one year ago. Receipts for the AXS unit, meantime, increased to $26.5 million from $24 million year over year.


R&D spending in the quarter for the Daltonics units inched up to $6.6 million from $5.1 million during the same period last year, and also increased to $3.2 million from $2.8 million for the ASX division, Bruker said.


As a result, Bruker Daltonics in the current second quarter posted a net loss of $200,000, or $0 per share, down from $4.2 million, or $.08 per share, in the year-ago period. Bruker AXS, meantime, reported net losses of $2 million, or $.03 per share, up from $600,000, or $.01 per share, year over year.


Bruker Daltonics said it had around $46.8 million in cash and short-term investments as of June 30, and Bruker AXS said it had roughly $48 million through the same period.


Click here for more information.



The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.